Lista de obras - Marc Buyse - Dominio Público Uruguay

A perspective on surrogate endpoints in controlled clinical trials

artículo científico publicado en 2004

A statistical approach to central monitoring of data quality in clinical trials

artículo científico publicado en 2012

A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials

artículo científico publicado en 2009

Adjuvant trastuzumab in HER2-positive breast cancer

artículo científico publicado en 2011

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

artículo científico publicado en 2010

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

artículo científico publicado en 2012

Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia ⬇️

artículo científico publicado el 23 de marzo de 2011

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set

artículo científico publicado en 2009

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

artículo científico publicado en 2010

Biomarkers and surrogate end points--the challenge of statistical validation

artículo científico publicado en 2010

Challenges in breast cancer clinical trial design in the postgenomic era.

artículo científico publicado en 2004

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

artículo científico publicado en 2015

Common pitfalls in statistical analysis: Clinical versus statistical significance

artículo científico publicado en 2015

Comparison of prognostic gene expression signatures for breast cancer

artículo científico publicado en 2008

Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer

artículo científico publicado en 2002

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

artículo científico publicado en 2009

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy

artículo científico publicado en 2012

Current issues in adjuvant treatment of stage II colon cancer

artículo científico publicado en 2006

Data fraud in clinical trials

artículo científico publicado en 2015

Data sharing, year 1--access to data from industry-sponsored clinical trials

artículo científico publicado en 2014

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

artículo científico publicado en 2005

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

artículo científico publicado en 2007

End points in advanced colon cancer clinical trials: a review and proposal

artículo científico publicado en 2007

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

artículo científico publicado en 2008

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials

artículo científico publicado en 2007

Ensuring trial validity by data quality assurance and diversification of monitoring methods

artículo científico publicado en 2008

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials

artículo científico publicado en 2009

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

artículo científico publicado en 2004

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

artículo científico publicado en 2006

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer

artículo científico publicado en 2013

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

artículo científico publicado en 2011

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

artículo científico publicado en 2011

Integrating biomarkers in clinical trials

scientific article published on March 2011

Meta-analysis based on individual patient data: example of advanced colorectal cancer

artículo científico publicado en 2010

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

artículo científico publicado en 2010

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

Omics-based clinical trial designs

artículo científico publicado en 2013

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

artículo científico publicado en 2010

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

artículo científico publicado en 2011

Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time

artículo científico publicado en 2011

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials ⬇️

artículo científico publicado el 13 de marzo de 2013

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

artículo científico publicado en 2012

Progress in the medical treatment of advanced colorectal cancer ⬇️

artículo científico publicado el 1 de octubre de 2003

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis

scientific article published on 09 October 2013

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis ⬇️

artículo científico publicado el 24 de enero de 2013

Statistical challenges in the evaluation of surrogate endpoints in randomized trials

artículo científico publicado en 2002

Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial

artículo científico publicado en 2015

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

artículo científico publicado en 2009

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

artículo científico publicado en 2015

The ARCAD Clinical Trials Program: An Update and Invitation ⬇️

artículo científico publicado el 2 de febrero de 2012

The impact of data errors on the outcome of randomized clinical trials

artículo científico publicado en 2017

Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials

scientific article published on September 2009

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

artículo científico publicado en 2006

Lista de obras de Marc Buyse

A perspective on surrogate endpoints in controlled clinical trials

A statistical approach to central monitoring of data quality in clinical trials

A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials

Adjuvant trastuzumab in HER2-positive breast cancer

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia ⬇️

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis

Biomarkers and surrogate end points--the challenge of statistical validation

Challenges in breast cancer clinical trial design in the postgenomic era.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

Common pitfalls in statistical analysis: Clinical versus statistical significance

Comparison of prognostic gene expression signatures for breast cancer

Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy

Current issues in adjuvant treatment of stage II colon cancer

Data fraud in clinical trials

Data sharing, year 1--access to data from industry-sponsored clinical trials

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

End points in advanced colon cancer clinical trials: a review and proposal

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials

Ensuring trial validity by data quality assurance and diversification of monitoring methods

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Integrating biomarkers in clinical trials

Meta-analysis based on individual patient data: example of advanced colorectal cancer

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Omics-based clinical trial designs

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials ⬇️

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

Progress in the medical treatment of advanced colorectal cancer ⬇️

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis

Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis ⬇️

Statistical challenges in the evaluation of surrogate endpoints in randomized trials

Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

The ARCAD Clinical Trials Program: An Update and Invitation ⬇️

The impact of data errors on the outcome of randomized clinical trials

Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer